58 results about "Cardiac dysfunction" patented technology

The invention discloses a hospital obese patient intelligent weight loss dynamic matching intervention method and decision making system based on multi-modal data fusion, and relates to the field of medical health, and the method comprises the following steps: S1, carrying out the real-time collection and fusion of multi-modal data; s2, dynamic metabolism modeling and plateau period breakthrough; s3, generating a hierarchical intervention strategy; s4, performing psychological-physiological linkage intervention; and S5, performing real-time safety control and feedback optimization. By collecting multi-dimensional data, constructing the model, accurately predicting the metabolic rate, the metabolic plateau period and the sudden eating tendency, dynamically adjusting the exercise intensity and the diet scheme according to the conditions of different patients, triggering a low-intensity exercise mode for the obese patients with cardiac insufficiency and calibrating diet, ensuring the exercise safety, and improving the exercise efficiency. Operation suggestions are generated on the basis of the standard, precise preoperative evaluation is conducted, postoperative rehabilitation is optimized in combination with nerve stimulation data, dangerous postures are monitored, the sport injury risk is reduced, and personalized, safe and efficient intelligent weight reduction intervention for obese patients is achieved.

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

The invention relates to the technical field of image enhancement processing, in particular to an image enhancement method of a chest X-ray film for evaluating cardiac insufficiency. The method comprises the following steps: firstly, obtaining a shielding region of a normal X-ray film lung region, and projecting the shielding region to a target image to obtain a shielding part; further, according to similar characteristics of a skeleton line of the foreground connected domain and an edge line of a shielding part, combining an edge fuzzy characteristic and a local gray scale difference of the connected domain, obtaining a pulmonary blood vessel information amount of a pixel point and obtaining a pulmonary blood vessel region; further matching pixel points of the pulmonary vessel areas in the X-ray films which are inclined left and right according to the gray level change similarity in the vertical direction; and finally, carrying out translation superposition on the X-ray films which are inclined leftwards and rightwards on the basis of the overlapped pixel point group and the pulmonary blood vessel information amount, fitting a fused pulmonary blood vessel part to a shielding part, obtaining a pulmonary blood vessel X-ray image, matching translation superposition to repair a shielding region, overcoming oblique distortion and improving a pulmonary blood vessel display effect.

The invention discloses application of ADAMTS4 as a biomarker of sepsis with cardiac dysfunction, AUCROC is equal to 0.930, 95% CI is 0.859-1.000 in diagnosis of sepsis with cardiac dysfunction as the biomarker, accuracy is high, and a new detection means and scheme are provided for diagnosis and prediction of sepsis with cardiac dysfunction.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

A traditional Chinese medicine formula for treating blood vessel clogging belongs to the field of traditional Chinese medicine formulas, and comprises the following main raw materials: 29-31 parts of black pearl, 11-13 parts of codonopsis pilosula, 7-9 parts of saffron crocus, 8-10 parts of angelica sinensis, 190-210 parts of leek, 9-11 parts of pseudo-ginseng, 37-43 parts of hawthorn, 95-105 parts of astragalus membranaceus, 18-22 parts of kudzu vine root, 8-10 parts of peach kernel, 8-10 parts of prepared rehmannia root, 9-11 parts of radix rehmanniae, 11-13 parts of white paeony root, 3 parts of red ginseng, 9-11 parts of radix ophiopogonis, 14-16 parts of spina date seed, 11-13 parts of Chinese yam, 14-15 parts of schisandra chinensis, 9-11 parts of polygonum multiflorum, 7-9 parts of cinnamon, 18-21 , 13-15 parts of anise and 12-14 parts of rhizoma polygonati. The traditional Chinese medicine composition has an obvious improvement effect on coronary artery insufficiency, myocardial ischemia, mitral valve, tricuspid valve, aortic valve regurgitation, chronic heart failure, patients needing operation bypass stenting, angina pectoris, myocardial infarction sequelae, cerebral ischemia, cerebrovascular sequelae and other symptoms caused by cardiac insufficiency, the dosage is small, the effect is fast, the cure rate is high, relapse is not prone to occurring, and the traditional Chinese medicine composition is suitable for clinical application. The effects of tonifying qi and activating blood, dredging channels and relieving pain, eliminating phlegm and removing blood stasis, tonifying heart and soothing nerves and the like can be achieved.

The application relates to the fields of medical diagnosis and gene drugs, and particularly relates to application of long-chain non-coding RNA in preparation of a heart insufficiency diagnosis reagent or kit. The application also provides application of the long-chain non-coding RNA in preparation of a heart insufficiency treatment drug. The application first finds that LOC107984012 is long-chain non-coding RNA which is highly expressed in a failing heart, and provides a new diagnosis marker and treatment target for heart insufficiency.

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

This invention discloses a class of pyrazolopyridine compounds linked by an aza-four-membered ring, or pharmaceutically acceptable salts thereof, and their applications. These compounds can serve as novel, highly selective PDE10A inhibitors for the treatment of peripheral tissue diseases, including: myocardial hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal impairment and renal fibrosis, pulmonary inflammation and pulmonary fibrosis, immune dysregulation, and cancers (colon cancer, ovarian cancer, and lung cancer). Two strategies are employed to achieve high selectivity for PDE10A inhibition while simultaneously reducing the inhibitory effect on the central nervous system. First, molecular structure modification: structural optimization of the aza-four-membered ring-linked pyrazolopyridine compounds, such as increasing the ratio of N, O, and S atoms in the molecular structure to increase the polar surface area and reduce lipophilicity; and introducing hydrophilic groups to increase water solubility, thereby reducing the permeability of the compound to the blood-brain barrier (BBB). Second, targeted drug delivery to lung tissue via pharmaceutical formulation.

The application provides application of Trapidil in preparation of a drug for preventing and / or treating doxorubicin-induced organ toxicity, and belongs to the technical field of biological medicines.The application discloses that Trapidil plays an organ protection role by activating a cAMP / PKA / CREB signal axis and driving two parallel downstream effect channels: on the one hand, up-regulating an NRF2-GPX3 positive feedback loop to inhibit doxorubicin-induced myocardial cell pyroptosis and glomerular podocyte pyroptosis; and on the other hand, activating an NRF2 / HO-1 channel to inhibit myocardial cell apoptosis and glomerular podocyte apoptosis.In-vivo and in-vitro experiments prove that Trapidil can improve doxorubicin-induced cardiac dysfunction and kidney function damage, reduce histopathological damage, reduce the level of oxidative stress, inhibit the pyroptosis and apoptosis of myocardial cells and glomerular podocytes, and does not affect the antitumor effect of doxorubicin.The application provides a new drug strategy for doxorubicin chemotherapy-induced multi-organ toxicity.

The invention provides application of kestose in preparation of a medicine for treating heart failure related diseases, and belongs to the technical field of biological medicine. The prominent application value of the natural compound kestose in prevention and treatment of heart failure related diseases is disclosed for the first time. The traditional Chinese medicine composition has the direct effects of remarkably improving cardiac insufficiency and relieving myocardial injury; in the aspect of product application, a brand-new choice of a heart failure treatment medicine derived from a natural product is provided for clinic, the medicine has a good myocardial protection effect, a solid foundation is laid for developing a targeted treatment strategy aiming at a specific pathological link of chronic cross-induction, and the application has a wide application prospect. Important theoretical significance and wide clinical application prospects are realized.

The invention belongs to the field of biological medicine, particularly discloses pharmaceutical application of a Dio3 inhibitor screened based on a thyroid hormone disorder algorithm in sepsis cardiomyopathy, and discloses that the core pathological mechanism of SIC is thyroid hormone signal axis disorder caused by Dio3 abnormal up-regulation, further mitochondrial autophagy key protein is inhibited, and the application of the Dio3 inhibitor in sepsis cardiomyopathy is developed for the first time. And myocardial mitochondrial homeostasis imbalance and functional cardiac dysfunction are caused. Through single intraperitoneal injection (25mg / kg) of a compound PBENZ-DBRMD (specific Dio3 inhibitor) within 12 hours after sepsis occurs, heart function indexes (EF% / FS%) can be remarkably recovered, and mitochondrial autophagy disorder can be reversed. Meanwhile, serum transT3 (rT3) is provided as an SIC early diagnosis marker (rT3 is strongly negatively correlated with EF%). The scheme provides a new targeted intervention strategy for SIC, and has the characteristics of simplicity and convenience in operation and definite curative effect.

The invention discloses application of scopalactone in treatment of pulmonary arterial hypertension, and relates to the technical field of medicinal chemistry. The scoparone is applied to preparation of the medicine for treating pulmonary arterial hypertension. The medicine comprises scopalactone, a pharmaceutically acceptable carrier, a diluent and an excipient, the medicine further comprises other medicines for treating the pulmonary arterial hypertension, and the other medicines for treating the pulmonary arterial hypertension are selected from a prostacyclin medicine, an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. The scopalactone is applied to preparation of the medicine for treating pulmonary arterial hypertension, right heart insufficiency caused by hypoxia can be remarkably reversed, and the right heart function is effectively improved by reducing the transverse diameter of the right ventricle and the transverse diameter of the right atrium and improving the indexes such as tricuspid valve ring plane contraction displacement; the average pulmonary arterial pressure and right ventricular systolic pressure can be obviously reduced, and hemodynamic parameters are improved; the area and thickness of a blood vessel wall can be remarkably reduced, the blood vessel structure is improved, and pulmonary arteriole reconstruction is relieved.

This invention discloses the application of GW3965 in the preparation of drugs that alleviate cardiac damage caused by doxorubicin. Experiments have demonstrated that GW3965 can, while inhibiting tumor growth, alleviate cardiac dysfunction related to doxorubicin cardiotoxicity, reduce doxorubicin-induced cardiac fibrosis, and inhibit doxorubicin-induced cardiomyocyte atrophy and apoptosis. This suggests that GW3965 can alleviate cardiac damage caused by doxorubicin, increase the safety of doxorubicin chemotherapy, and has promising clinical application prospects.

The invention belongs to the field of biological medicine, and particularly relates to a novel compound and application thereof. The invention designs a novel 2-(1H-indol-3-yl)-N-(2-nitrobenzyl) ethylamine derivative as a selective normal allosteric modulator of nAChR, and discovers that the compound with the structure shows remarkable advantages in the aspect of preventing and / or treating cardiac malfunction diseases. The invention has the characteristics of fast, safe and effective prevention and termination of various arrhythmias, and provides a new drug choice for clinical treatment of cardiac dysfunction diseases.

The application provides a virus vector for specifically overexpressing ZER1 in myocardial cells and application in heart failure treatment. The application provides an expression vector, wherein the expression vector comprises a nucleotide sequence encoding ZER1, and the nucleotide sequence encoding ZER1 is operably connected to a myocardial specific promoter. The application also provides a pharmaceutical composition comprising the expression vector, and use of the expression vector or the pharmaceutical composition in preparation of a drug for preventing or treating cardiac dysfunction.

The invention belongs to the technical field of biological pharmacy, and provides application of American ginseng total saponins in preparation of a medicine for treating angiogenesis after myocardial infarction. Animal experiment results show that AGS can obviously improve cardiac functions of MI mice and cardiac dysfunction after myocardial infarction, and has obvious effects of improving endothelial cell functions and promoting angiogenesis. It is clear that the American ginseng total saponins may become a promising candidate drug for treating angiogenesis-related cardiovascular diseases in the future, and an effective technical means is provided for treatment of myocardial infarction.

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt and / or solvate thereof for use in the prevention and / or treatment of heart failure, cardiomyopathy, myocardial infarction-induced cardiac dysfunction and / or for improving cardiac function in a subject in need thereof.

The application provides a use of Di'ao Xin-xue-kang in preparation of a medicine for preventing doxorubicin-induced cardiac endothelial injury toxicity, and belongs to the field of medicines. The application uses Di'ao Xin-xue-kang for preventive administration, protects early cardiac endothelial injury induced by doxorubicin, and further can rescue or avoid occurrence of subsequent irreversible cardiotoxicity, especially uses Di'ao Xin-xue-kang for prevention or / and intervention of asymptomatic cardiac dysfunction related to cancer treatment, and opens a new use and administration method for clinical use of Di'ao Xin-xue-kang.

The invention discloses application of an HSPA13 gene in preparation of a product for improving diabetic cardiomyopathy, and belongs to the technical field of gene engineering. Aiming at the technical problems of myocardial microvascular endothelial cell glycolysis damage, perfusion insufficiency and cardiac dysfunction caused by long-term hyperglycemia, the invention firstly proves that in a streptozotocin-induced type 1 diabetes mouse model, the expression of HSPA13 in myocardial microvascular endothelial cells is remarkably reduced, and then an endothelium-targeted adeno-associated virus vector AAV-HSPA13 is constructed; and intravenous administration is carried out. Experimental results show that the vector can recover the endothelial glycolysis level, improve coronary flow reserve and significantly relieve the pathological change of DCM. The HSPA13 gene is taken as a core target, can be used for preparing or screening a pharmaceutical composition or a function evaluation model for treating DCM, and has outstanding innovativeness and clinical application prospect.

The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (A disintegrin and metalloproteinase with thrombospondin motifs 12-protein) in the pathogenesis of chronic kidney and heart diseases and in particular chronic renal insufficiency and renal fibrosis or cardiac insufficiency and cardiac fibrosis. The present invention relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, and to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active ingredients that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing and treating coronary artery microvascular disease caused by ischemia reperfusion injury and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 10 to 20 parts of rhizoma coptidis with ginger, 9 to 15 parts of rhizoma pinelliae with ginger, 15 to 30 parts of pericarpium trichosanthis, 5 to 15 parts of cassia twig, 5 to 30 parts of raw radix astragali seu hedysari and 15 to 30 parts of radix salviae miltiorrhizae. Animal experiments show that the composition can improve heart blood perfusion, protect capillary structures and barrier functions and reduce myocarditis, thereby improving cardiac dysfunction. Cell experiments prove that the compound can activate endothelial cell mitochondria autophagy, eliminate damaged mitochondria, relieve oxidative stress and cell apoptosis and improve the endothelial function. In conclusion, the composition plays an endothelial protection role by promoting microcirculation perfusion and activating mitochondrial autophagy, and coronary artery microvascular dysfunction caused by ischemia reperfusion injury is effectively prevented and treated.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.

The invention discloses application of NINJ1 in treatment of adriamycin-induced myocardial injury, and relates to the field of biological medicine. The NINJ1 is applied to preparation of a medicine for preventing and / or treating adriamycin-induced myocardial injury, and the application comprises the step of achieving the purpose of preventing and / or treating adriamycin-induced myocardial cell injury, cardiac insufficiency, myocardial fibrosis or heart failure by inhibiting expression or activity of NINJ1. Wherein the mode of inhibiting the NINJ1 comprises the use of an NINJ1 inhibitor, the knockout of an NINJ1 gene or the silencing of the NINJ1 gene. The key effect of the NINJ1 in doxorubicin cardiotoxicity is disclosed for the first time, the NINJ1 is determined as a new therapeutic target, a new direction and theoretical basis are provided for development of drugs for preventing and treating doxorubicin cardiotoxicity, and the NINJ1 has important clinical value.

This invention belongs to the field of biomedicine, specifically relating to a novel compound and its applications. This invention designs a novel 2-(1H-indol-3-yl)-N-(2-nitrobenzyl)ethylamine derivative as a selective orthoallosteric modulator of nAChR, and discovers that compounds with this structure exhibit significant advantages in the prevention and / or treatment of cardiac dysfunction, possessing the characteristics of rapid, safe, and effective prevention and termination of various arrhythmias, providing a new drug option for the clinical treatment of cardiac dysfunction.

The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.

This invention relates to the field of image enhancement processing technology, specifically to an image enhancement method for chest X-rays used to assess heart failure. The invention first obtains the occluded region of the lung area from an orthogonal X-ray and projects it onto a target image to obtain the occluded portion. Further, based on the similarity between the skeleton lines of the foreground connected components and the edge lines of the occluded portion, combined with the edge blurring features of the connected components and local gray-level differences, the pulmonary vascular information of each pixel is obtained, and the pulmonary vascular region is acquired. Further, based on the similarity of gray-level changes in the vertical direction, pixels in the pulmonary vascular region of left and right anterior oblique X-rays are matched. Finally, based on the overlapping pixel groups and the pulmonary vascular information, the left and right anterior oblique X-rays are translated and superimposed, and the fused pulmonary vascular portion is fitted to the occluded portion to obtain a pulmonary vascular X-ray image. Matching, translation, and superimposition repair the occluded area, overcomes oblique distortion, and improves the display effect of pulmonary vessels.